Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.
- DOI
- 10.1002/oby.70301
- Published
- 2026 Sep 22
- Container
- Obesity (Silver Spring, Md.)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1002/oby.70301,
title = {Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.},
author = {Orandi BJ and Yan L and Levan ML and Lofton HF and Chhabra KR and Ren-Fielding CJ and Husain SA and McAdams-DeMarco MA and Segev DL and Mankowski MA and Massie AB},
year = {2026},
journal = {Obesity (Silver Spring, Md.)},
doi = {10.1002/oby.70301},
url = {https://doi.org/10.1002/oby.70301}
}RIS
TY - JOUR TI - Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication. AU - Orandi BJ AU - Yan L AU - Levan ML AU - Lofton HF AU - Chhabra KR AU - Ren-Fielding CJ AU - Husain SA AU - McAdams-DeMarco MA AU - Segev DL AU - Mankowski MA AU - Massie AB PY - 2026 JO - Obesity (Silver Spring, Md.) DO - 10.1002/oby.70301 UR - https://doi.org/10.1002/oby.70301 ER -
APA
BJ, O., L, Y., ML, L., HF, L., KR, C., CJ, R., SA, H., MA, M., DL, S., MA, M., & AB, M. (2026). Trends in GLP-1 Receptor Agonist Prescribing Without an Apparent FDA-Approved Indication.. Obesity (Silver Spring, Md.). https://doi.org/10.1002/oby.70301
Source records
- pubmed · retrieved 2026-09-24T19:33:02.189Z